DeepMed Research

Celldex Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1983-01-01

Employees: 160

Market Cap: $2.5B

Website: http://www.celldex.com

Clinical Trials

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Phase 2

Recruiting

Conditions: Atopic Dermatitis

Interventions: Biological: Barzolvolimab
Drug: Matching placebo

First Posted Date: 2024-12-11

Last Posted Date: 2025-05-20

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 120

Registration Number: NCT06727552

Locations: 🇺🇸
Ohara Aivaz MD Dermatology, Beverly Hills, California, United States
🇺🇸
Georgia Skin and Cancer Clinic, Savannah, Georgia, United States
🇺🇸
Avance Trials, Laguna Niguel, California, United States

and more 21 locations

A Phase I Study of CDX-622

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: CDX-622
Drug: Normal Saline

First Posted Date: 2024-10-21

Last Posted Date: 2025-04-17

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 56

Registration Number: NCT06650761

Locations: 🇺🇸
Celerion, Inc., Tempe, Arizona, United States

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Phase 3

Recruiting

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: barzolvolimab
Biological: Matching placebo

First Posted Date: 2024-06-12

Last Posted Date: 2025-05-06

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 915

Registration Number: NCT06455202

Locations: 🇨🇦
LEADER research, Hamilton, Ontario, Canada
🇺🇸
Allervie Clinical Research - Cullman, Cullman, Alabama, United States
🇺🇸
Research Solutions of Arizona PC, Litchfield Park, Arizona, United States

and more 145 locations

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Phase 3

Recruiting

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: barzolvolimab
Biological: Matching placebo

First Posted Date: 2024-06-06

Last Posted Date: 2025-05-02

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 915

Registration Number: NCT06445023

Locations: 🇧🇪
Dermatologie Maldegem, Maldegem, Belgium
🇺🇸
Premier Clinical Research, Spokane, Washington, United States
🇧🇪
UZ Antwerp, Edegem, Antwerpen, Belgium

and more 192 locations

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Phase 2

Recruiting

Conditions: Prurigo Nodularis

Interventions: Biological: barzolvolimab
Other: Matching Placebo

First Posted Date: 2024-04-16

Last Posted Date: 2025-03-30

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 120

Registration Number: NCT06366750

Locations: 🇺🇸
Total Dermatology, Birmingham, Alabama, United States
🇺🇸
Investigate MD, LLC, Scottsdale, Arizona, United States
🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States

and more 49 locations

A Study of CDX-585 in Patients With Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer
Esophageal Cancer
Non-small Cell Lung Cancer
Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Bladder Urothelial Carcinoma
Hepatic Cancer
Gastric Cancer
Head and Neck Cancer

Interventions: Drug: CDX-585

First Posted Date: 2023-03-29

Last Posted Date: 2025-04-16

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 130

Registration Number: NCT05788484

Locations: 🇺🇸
George Washington University Cancer Center, Washington, District of Columbia, United States
🇺🇸
AdventHealth Celebration, Celebration, Florida, United States
🇺🇸
Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States

and more 1 locations

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Phase 2

Active, not recruiting

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Matching Placebo
Biological: barzolvolimab

First Posted Date: 2023-03-17

Last Posted Date: 2025-04-03

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 86

Registration Number: NCT05774184

Locations: 🇺🇸
AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸
One of a Kind Clinical Research Center, Scottsdale, Arizona, United States
🇺🇸
GI Alliance- Arizona Digestive Health- Sun City, Sun City, Arizona, United States

and more 50 locations

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Phase 2

Active, not recruiting

Conditions: Chronic Inducible Urticaria

Interventions: Biological: barzolvolimab
Drug: Matching Placebo

First Posted Date: 2022-06-06

Last Posted Date: 2024-07-03

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 196

Registration Number: NCT05405660

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny nr 1 w Lodzi, Lodz, Poland
🇺🇸
Allergy & Asthma Specialists, PSC, Owensboro, Kentucky, United States
🇿🇦
Synapta Clinical Research, Durban, KwaZulu-Natal, South Africa

and more 72 locations

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: barzolvolimab
Drug: Matching Placebo

First Posted Date: 2022-05-10

Last Posted Date: 2025-03-26

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 208

Registration Number: NCT05368285

Locations: 🇺🇸
Treasure Valley Medical Research, Boise, Idaho, United States
🇺🇸
Kern Research, Inc, Bakersfield, California, United States
🇺🇸
Allergy & Asthma Specialists, PSC, Owensboro, Kentucky, United States

and more 53 locations

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: CDX-0159
Drug: Normal saline

First Posted Date: 2021-09-02

Last Posted Date: 2022-01-21

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 32

Registration Number: NCT05031624

Locations: 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy